It has previously been shown that extracts of tumours associated with the ectopic production of ACTH contain, in addition to intact ACTH, COOH-and NH27terminal fragmnents of the ACTH molecule which are normally only found in the pituitaries of animals possessing a distinct pars intermedia. We believed it possible that these tumours might also contain, in addition to intact /3-LPH, fragmnents of the /3-LPH molecule such as y-LPH and fl-MSH which are also associated with the presence of a pars intermedia. A peptide, eluting on Biogel P6 gel filtration in an identical position to bovine /3-MSH, was identified in a glacial acetic acid extract of an ovarian metastasis of a bronchial carcinoid tumour. Material resembling fl-LPH was also found. An HCI/acetone extract of a medullary carcinoma of the thyroid contained immunoreactive peptides with similar molecular weights to /3and y-LPH. No peptide resembling 'human /3-MSH' was identified in any tumour.
Thus, while the situation in some human tumours appears to differ from that found in the human pituitary, it is still not clear whether this is due to the presence of specific cleavage enzymes in the tumours, or is merely the result of increased catabolic activity in rapidly growing, necrosing tissue.
Acknowledgment: This work has been generously supported by grants from the Cancer Research Campaign and the Tenovus Institute. 
Hormonal Effects of Synthetic ACTH Analogues
It is well established that patients with diseases such as rheumatoid arthritis and bronchial asthma may respond clinically to high levels of plasma corticosteroids, which may be achieved either by oral synthetic steroid, such as prednisone or by subcutaneous or intramuscular injection of corticotrophin (ACTH). In recent years there has been a trend away from the use of steroids which in daily divided dosage, in excess of the equivalent of 7.5 mg prednisone, usually cause the suppression of the hypothalamopituitary-adrenal axis with subsequent failure of the patient to respond to stress (Treadwell et al. 1963 , Landon et al. 1965 , Livanou et al. 1967 , Jasani et al. 1967 ). On the other hand, both animal ACTH preparations and synthetic ACTH analogues, such as al-24 ACTH zinc (tetracosactrin depot), will give rise to therapeutic levels of plasma corticosteroids without suppressing the brain-adrenal axis if used in appropriate dosage (Bacon et al. 1968 , Carter & James 1970 , Irvine etal. 1971 .
Recently, a new polypeptide has been synthesized, consisting of the first 18 amino-acids of natural ACTH, substituted at positions 1, 17 and 18 by d-serine, lysine and lysine respectively (Desaulles et al. 1969) . Termed substituted al-18 ACTH, it has a prolonged corticotrophic action (Keenan et al. 1971 , Irvine et al. 1974 resulting from the modification of the peptide sequence and has the advantage over al-24 ACTH Zn of subcutaneous administration. Irvine et aL (1973) showed substituted al-18 ACTH in a dose of 0.25 mg subcutaneously to give rise to therapeutic levels of plasma 11hydroxycorticosteroids (11-OHCS) for most of the day in 8 healthy subjects, and in 6 of the 8 allowed the endogenous secretion of ACTH in the early hours of the morning as evidenced by plasma 1 -OHCS being higher at 0800 hours than 0300 hours on the day following the injection. In theory, at least, the daily use of such a preparation should not suppress the brainadrenal axis in the majority of patients.
In a further study (Irvine et al. 1974) (Wilson & Fraser 1971 ) and plasma aldosterone measured by radioimmunoassay ). On the other hand the plasma aldosterone levels were not elevated in response to al-24 ACTH Zn 1 mg i.m. in two patients with collagenoses treated with al-24 ACTH Zn 0.5 mg i.m. twice weekly for many months. There was a rise, however, in plasma DOC levels. The lack of response of plasma aldosterone in such patients is unlikely to be related to salt and water retention acting via the renin-angiotensin system as plasma renin levels are uninfluenced by long term ACTH therapy (Newton & Laragh 1968) . It has been shown by Vescei (Vescei & Glaz 1971 ) that rat adrenals rendered hypertrophic by chronic ACTH adminstration have a reduced activity of 18-hydroxylase and 1 8-dehydrogenase, which are enzymes playing a prominent part in the biosynthesis of aldosterone, and it is conceivable that a similar situation exists in ACTH-treated man. Aldosterone excess, therefore, has little or no part in the pathogenesis of the hypertension found in 27% of patients on long term ACTH therapy (Treadwell et al. 1964) , and the role of DOC and 1 -OHCS deserves more attention. Irvine et al. (1974) were also able to demonstrate a marked rise in Plasma A4-androstenedione measured by radioimmunoassay (Thorneycroft et al. 1973 ) after each synthetic ACTH preparation in the' dexamethasone-suppressed males. In contrast, the plasma level of the major androgen, testosterone, measured by radioimmunoassay without chromatography (Ismail et al. 1972) fell to a nadir 14 hours after each ACTH analogue. The fall was not dependent upon pituitary gonadotrophins as plasma folliclestimulating hormone and luteinizing hormone levels measured by radioimmunoassay (I were unchanged throughout the 24 hours of study. ACTH may exert its influence, therefore, directly on the interstitial cell of the testis possibly by altering the pattern of steroidogenesis within the cell. Support for such a hypothesis is gained from the observation that plasma testosterone levels fell in a patient with Addison's disease following substituted al-18 ACTH 1 mg i.m.
Whether the fall in plasma testosterone concentration induced by chronic ACTH treatment is associated with a high incidence of sexual disorders such as impotence, or whether sexual function is maintained by the increased secretion of the weaker adrenocortical androgens such as j14-androstenedione remains to be determined. The following papers were also read: 
